KR20100014947A - 4-아닐린 퀴나졸린 유도체의 염 - Google Patents

4-아닐린 퀴나졸린 유도체의 염 Download PDF

Info

Publication number
KR20100014947A
KR20100014947A KR1020097018740A KR20097018740A KR20100014947A KR 20100014947 A KR20100014947 A KR 20100014947A KR 1020097018740 A KR1020097018740 A KR 1020097018740A KR 20097018740 A KR20097018740 A KR 20097018740A KR 20100014947 A KR20100014947 A KR 20100014947A
Authority
KR
South Korea
Prior art keywords
salt
pharmaceutically acceptable
acid
salts
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097018740A
Other languages
English (en)
Korean (ko)
Inventor
지안후이 구오
용 지앙
Original Assignee
상하이 알리스트 파르마슈티컬 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상하이 알리스트 파르마슈티컬 인코포레이티드 filed Critical 상하이 알리스트 파르마슈티컬 인코포레이티드
Publication of KR20100014947A publication Critical patent/KR20100014947A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020097018740A 2007-02-14 2008-02-04 4-아닐린 퀴나졸린 유도체의 염 Ceased KR20100014947A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200710037557.2 2007-02-14
CNA2007100375572A CN101245050A (zh) 2007-02-14 2007-02-14 4-苯胺喹唑啉衍生物的盐

Publications (1)

Publication Number Publication Date
KR20100014947A true KR20100014947A (ko) 2010-02-11

Family

ID=39689656

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097018740A Ceased KR20100014947A (ko) 2007-02-14 2008-02-04 4-아닐린 퀴나졸린 유도체의 염

Country Status (8)

Country Link
US (1) US8349854B2 (enExample)
EP (1) EP2116540B1 (enExample)
JP (1) JP5504460B2 (enExample)
KR (1) KR20100014947A (enExample)
CN (3) CN101245050A (enExample)
AU (1) AU2008215053B2 (enExample)
CA (1) CA2677978C (enExample)
WO (1) WO2008098485A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101347433B (zh) * 2007-07-20 2012-05-02 江苏艾力斯生物医药有限公司 4-苯胺喹唑啉衍生物的制药用途
CN101544609A (zh) * 2008-03-25 2009-09-30 上海艾力斯医药科技有限公司 4-苯胺喹唑啉衍生物的结晶形式
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
MY196809A (en) * 2015-12-24 2023-05-03 Kyowa Kirin Co Ltd (),()-unsaturated amide compound
CN106117182B (zh) * 2016-06-20 2019-08-30 中国药科大学 喹唑啉-n-苯乙基四氢异喹啉类化合物及其制备方法和应用
CN112225679A (zh) * 2020-10-13 2021-01-15 苏州亚科科技股份有限公司 一种3-(环己胺)-2-羟基-1-丙磺酸的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
CA2216796C (en) 1995-03-30 2003-09-02 Pfizer Inc. Quinazoline derivatives
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
ATE309225T1 (de) 1998-07-30 2005-11-15 Wyeth Corp Substituierte chinazoline derivate
JP4102185B2 (ja) * 2000-06-30 2008-06-18 グラクソ グループ リミテッド キナゾリンジトシル酸塩化合物
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
CN101003514A (zh) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途

Also Published As

Publication number Publication date
CN101668750A (zh) 2010-03-10
CA2677978A1 (en) 2008-08-21
CA2677978C (en) 2015-04-07
CN101245050A (zh) 2008-08-20
US20100168142A1 (en) 2010-07-01
WO2008098485A1 (en) 2008-08-21
JP5504460B2 (ja) 2014-05-28
AU2008215053B2 (en) 2013-10-24
EP2116540A1 (en) 2009-11-11
EP2116540A4 (en) 2010-04-28
EP2116540B1 (en) 2014-08-13
US8349854B2 (en) 2013-01-08
CN104628658B (zh) 2015-10-21
AU2008215053A1 (en) 2008-08-21
CN104628658A (zh) 2015-05-20
JP2010518173A (ja) 2010-05-27

Similar Documents

Publication Publication Date Title
CN107556295B (zh) 喹唑啉衍生物及其制备方法
RU2417230C2 (ru) N2-хинолил- или изохинолилзамещенные производные пурина, способы их получения и использования
EP2248806B1 (en) Quinazoline derivatives as tyrosine kinase inhibitors
US20180230154A1 (en) Atropisomerism for increased kinase inhibitor selectivity
CA2330447C (en) N-(3-ethynylphenyl-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US9102629B2 (en) Polymorphic forms of 4-phenylamine quinazoline derivative, the preparation method and uses thereof
JP2019518776A (ja) Ｅｇｆｒ阻害剤としてのアニリンピリミジン化合物の結晶
US20190100509A1 (en) Salt of pyridinyl amino pyrimidine derivative, preparation method therefor, and application thereof
KR20100014947A (ko) 4-아닐린 퀴나졸린 유도체의 염
CN109988110B (zh) 4-苯氧基喹啉并磺酰脲类化合物、合成该化合物的中间体及其制备方法和用途
CN111499583A (zh) 喹唑啉衍生物及其作为抗肿瘤药物的应用
WO2009012702A1 (fr) Utilisation d'un dérivé de 4-aniline quinazoline pour la préparation de médicaments
CN116655600A (zh) 一种取代的2-芳氨基嘧啶类化合物、药物组合物及其用途
TWI394757B (zh) 嘌呤衍生物及使用它之抗腫瘤劑

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090908

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20101130

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120920

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130429

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120920

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20130530

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20130429

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2013101004104

Request date: 20130530

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20130628

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20130530

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20121123

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20130806

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20130530

Effective date: 20140404

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20140404

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20130530

Decision date: 20140404

Appeal identifier: 2013101004104